As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The decision is based on the phase 3 DESTINY-Breast11 trial
The new assay consolidates screening for four major viral threats into a single workflow
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Subscribe To Our Newsletter & Stay Updated
